DR. DERMOT P MCGOVERN, M.D., PH.D., MRCP
Osteopathic Medicine at Beverly Blvd, Los Angeles, CA
License number
California SFP000014
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
8700 Beverly Blvd, Los Angeles, CA 90048
Phone
(310) 423-4100
(310) 967-1800 (Fax)
(310) 967-1800 (Fax)
Personal information
See more information about DERMOT P MCGOVERN at radaris.comName
Address
Phone
11326 Gladwin St, Los Angeles, CA 90049
Professional information
Methods Of Predicting The Need For Surgery In Crohn's Disease
US Patent:
2012020, Aug 16, 2012
Filed:
Feb 13, 2012
Appl. No.:
13/372359
Inventors:
Marla C. Dubinsky - Los Angeles CA, US
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68, A61P 1/00, A61P 29/00, A61K 45/00
US Classification:
514789, 435 611
Abstract:
The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.
Methods Of Predicting Medically Refractive Ulcerative Colitis (Mr-Uc) Requiring Colectomy
US Patent:
2012005, Mar 1, 2012
Filed:
Dec 24, 2009
Appl. No.:
13/140874
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Encino CA, US
Dermot P. McGovern - Los Angeles CA, US
Xiuqing Guo - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Encino CA, US
Dermot P. McGovern - Los Angeles CA, US
Xiuqing Guo - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 38/12, A61K 31/56, C40B 40/06, A61B 17/00, C12Q 1/68, C40B 30/04
US Classification:
514 211, 435 611, 506 9, 506 16, 128898, 514179
Abstract:
Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
Dr. Dermot P Mcgovern - MD (Doctor of Medicine)
Hospitals:
Inflammatory Bowel Disease Ctr
8730 Alden Dr SUITE 2E, Los Angeles 90048
Inflammatory Bowel Disease Ctr
8730 Alden Dr SUITE 2E, Los Angeles 90048
8730 Alden Dr SUITE 2E, Los Angeles 90048
Inflammatory Bowel Disease Ctr
8730 Alden Dr SUITE 2E, Los Angeles 90048
Methods Of Diagnosing And Treating Intestinal Granulomas And Low Bone Density In Inflammatory Bowel Disease
US Patent:
2014001, Jan 16, 2014
Filed:
Mar 26, 2012
Appl. No.:
14/007391
Inventors:
Dermot P. McGovern - Los Angeles CA, US
Marla C. Dubinsky - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Jerome I. Rotter - Los Angeles CA, US
Marla C. Dubinsky - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Jerome I. Rotter - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68, G01N 33/68
US Classification:
514789, 435 611
Abstract:
The present invention relates to methods of diagnosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of at least one risk genetic variant is indicative of granuloma. In another embodiment, the presence of at least one risk genetic variant is indicative of low bone density (LBD).
Methods Of Using Genetic Variants To Diagnose And Predict Inflammatory Bowel Disease
US Patent:
2010024, Sep 23, 2010
Filed:
Oct 20, 2008
Appl. No.:
12/675718
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Xiaowen Su - Beverly Hills CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Xiaowen Su - Beverly Hills CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus.
The Role Of Il17Rd And The Il23-1L17 Pathway In Crohn's Disease
US Patent:
2011017, Jul 21, 2011
Filed:
Oct 1, 2009
Appl. No.:
13/121929
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Dermot P. McGovern - Los Angeles CA, US
Ling Mei - Pasadena CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68, C40B 30/04
US Classification:
506 9, 435 611
Abstract:
The present invention relates to methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility variants at the IL17RD locus. in one embodiment, the present invention provides a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease.
Methods Of Diagnosing Ulcerative Colitis And Crohn's Disease
US Patent:
2014001, Jan 16, 2014
Filed:
Mar 26, 2012
Appl. No.:
14/007381
Inventors:
Kent D. Taylor - Ventura CA, US
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Los Angeles CA, US
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
G01N 33/68
US Classification:
435 792
Abstract:
The present invention relates to methods of prognosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of risk serological marker ANCA is indicative of an aggressive form of ulcerative colitis. In another embodiment, the present invention relates to methods of diagnosing a Crohn's disease subtype in an individual, where the presence of risk variants and serological markers I2, OmpC and/or Cbir1 are indicative of the Crohn's disease subtype.
Methods Of Using Fut2 Genetic Variants To Diagnose Crohn's Disease
US Patent:
2013013, May 30, 2013
Filed:
Jan 14, 2011
Appl. No.:
13/521622
Inventors:
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
424 934, 506 2
Abstract:
The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the FUT2 genetic locus.
Methods Of Predicting Thiopurine Response
US Patent:
2012019, Jul 26, 2012
Filed:
Jan 25, 2012
Appl. No.:
13/358424
Inventors:
Marla Dubinsky - Los Angeles CA, US
Dermot P. McGovern - Los Angeles CA, US
Dermot P. McGovern - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 31/52, A61P 35/02, A61P 1/00, C12Q 1/68, A61P 29/00
US Classification:
5142633, 435 611
Abstract:
The present invention relates to methods of predicting therapeutic efficacy of thiopurines in an individual by determining the presence of one or more risk variants. In one embodiment, the effective therapeutic efficacy of thiopurines is determined by the presence of risk variants at the genetic loci of HLA-DRB1, CREM, TAGAP, PLCL1, GPX4, SBNO2, MEF2A and/or LYSMD4. In another embodiment, the risk variants are located at the genetic loci of ARL4C, IL1R2, JAK2, 19q13, CARD9, SNAPC4, and/or 8q24. In another embodiment, the individual is has been diagnosed with inflammatory bowel disease.